Over 30 state attorneys general including in Indiana, Kentucky, and Ohio have urged the Federal Food and Drug Administration to take action against "bad actors" selling counterfeit weight loss drugs.

Federal regulators say a new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug. The Food and Drug Administration approved Zepbound on Wednesday. The drug has been shown to help dieters lose about a quarter of their body weight, or 60 pounds. It is the latest diabetes drug approved for weight loss, joining Novo Nordisk’s Wegovy, a high-dose version of Ozempic. Short supply and high costs have limited access to both medications. The FDA approved the new drug for people considered obese or for those who are overweight and have a weight-related health condition.

Eli Lilly's diabetes treatment Mounjaro, which is widely used for weight loss, raked in nearly $1 billion in second-quarter sales, or more than $200 million above what Wall Street had expected.